T1	Participants 203 317	AQ-J was administered to 25 normally intelligent high-functioning pervasive developmental disorder (HPDD) patients
T2	Participants 450 468	general population
T3	Participants 701 709	controls
T4	Participants 911 932	25 mild HPDD patients
T5	Participants 1485 1492	persons
